UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 26, 2015
PROVECTUS BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)
| Delaware | 001-36457 | 90-0031917 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
7327 Oak Ridge Hwy., Knoxville, Tennessee 37931
(Address of Principal Executive Offices)
(866) 594-5999
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 7.01. | Regulation FD Disclosure. |
On June 26, 2015, Provectus Biopharmaceuticals, Inc. (the “Company”) issued a press release (the “Munich Press Release”) announcing that Dr. Vernon Sondak (Moffitt Cancer Center, Tampa, Florida) presented data on “Intralesional Therapy for Melanoma with PV-10” during the 5th European Post-Chicago Melanoma/Skin Cancer Meeting in Munich, Germany. A copy of the Munich Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
On June 26, 2015, the Company issued a press release (the “AAPI Press Release”) announcing that the American Association of Physicians of Indian Origin (“AAPI”) honored the Company at a gala during the AAPI’s 33rd Annual Convention and Scientific Assembly on Friday, June 19, 2015, held at the Renaissance Hotel Convention Center in Orlando, Florida. A copy of the AAPI Press Release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
Pursuant to the rules and regulations of the Securities and Exchange Commission, the information in this Item 7.01 disclosure, including Exhibits 99.1 and 99.2 and information set forth therein, is deemed to have been furnished and shall not be deemed to be “filed” under the Securities Exchange Act of 1934.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| Exhibit |
Description | |
| 99.1 | Munich Press Release, dated June 26, 2015 | |
| 99.2 | AAPI Press Release, dated June 26, 2015 | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 26, 2015
| PROVECTUS BIOPHARMACEUTICALS, INC. | ||
| By: | /s/ Peter R. Culpepper | |
| Peter R. Culpepper | ||
| Chief Financial Officer and Chief Operating Officer | ||
2
EXHIBIT INDEX
| Exhibit |
Description | |
| 99.1 | Munich Press Release, dated June 26, 2015 | |
| 99.2 | AAPI Press Release, dated June 26, 2015 | |